Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer

Volume: 142, Issue: 1, Pages: 157 - 165
Published: Jul 21, 2015
Abstract
Human epidermal growth factor receptor 2 (HER2) heterodimerizes and shares common signaling pathways with epidermal growth factor receptor (EGFR). In this study, we investigated the clinical implication of amphiregulin, a ligand for EGFR, on trastuzumab therapy in HER2-positive breast cancer. Serum amphiregulin levels were quantified in 50 consecutive patients with HER2-positive metastatic breast cancer who received first-line trastuzumab plus...
Paper Details
Title
Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer
Published Date
Jul 21, 2015
Volume
142
Issue
1
Pages
157 - 165
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.